At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 17 enrolled
Drug / intervention
Dexmedetomidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neuroimaging Study of Dexmedetomidine-Induced Analgesia
In Brief
A Phase 3 clinical trial evaluating Dexmedetomidine for Analgesia and Anesthesia. Completed, enrolled 17 participants across 1 site.
Detailed Summary
Neuroimaging data will be collected for patients that are given low doses of dexmedetomidine in order to understand its analgesic effects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnalgesia, Anesthesia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2022
Primary CompletionMay 2025
TodayJul 2026
First PostedDec 7, 2020
Enrollment StartMar 4, 2022
Primary CompletionMay 27, 2025
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.6 years ago
Interventions
Dexmedetomidinedrug
Patients will be delivered dexmedetomidine anesthesia to gain greater understanding of its analgesic effects.